Grant: FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.
FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.
CDFA Program Title
Trans-NIH Recovery Act Research Support
The E4508 randomized phase II clinical trial will evaluate the combination of chemotherapy with EGFR inhibition, IGF-1R inhibition or both. Although the clinical study accrual rate is estimated at 12 months, there will be an interim toxicity analysis requ
Recipients Connected to Award
|REGENTS OF THE UNIVERSITY OF COLORADO, THE||Sub-recipient||$403,691.00|
|FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.||Primary recipient||$271,085.00|
|DANA-FARBER CANCER INSTITUTE, INC.||Sub-recipient||$15,265.00|
|UNIVERSITY OF WISCONSIN SYSTEM||Sub-recipient||$9,547.00|